Welcome to Psychiatryai.com: Latest Evidence - RAISR4D

Effects of Empagliflozin and Lifestyle Intervention on Improving Body Weight and Other Metabolic Parameters in Atypical Antipsychotics-treated Patients with Schizophrenia Spectrum Disorders-A Double-blind Randomized Placebo-controlled Trial

Schizophr Bull. 2026 Apr 10;52(3):sbag050. doi: 10.1093/schbul/sbag050.ABSTRACTBACKGROUND AND HYPOTHESIS: Patients with schizophrenia spectrum disorders have elevated cardiovascular risk with obesity and deranged metabolic profiles associated...
close chatgpt icon
ChatGPT

Enter your request.

Psychiatry AI: Real-Time AI Scoping Review